Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]-Etrumadenant in Healthy Men
NCT05411146Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of etrumadenant in solid tumor, sponsored by Arcus Biosciences. Primary endpoints: Excretion of total radioactivity in urine up to 25 days, Excretion of total radioactivity in feces up to 25 days and 4 more. Started May 2022; status: completed.
02
Drugs
etrumadenant
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05411146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411146.